Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Medgenics Inc Common Stock (MDGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 200,330
  • Shares Outstanding, K 37,080
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,990 K
  • 36-Month Beta 1.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.23
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/03/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.96 +12.30%
on 12/02/16
5.95 -6.39%
on 11/17/16
+0.07 (+1.27%)
since 11/15/16
3-Month
4.00 +39.25%
on 11/03/16
5.95 -6.39%
on 11/17/16
+0.46 (+9.00%)
since 09/15/16
52-Week
3.09 +80.26%
on 02/11/16
6.60 -15.61%
on 06/14/16
-0.51 (-8.39%)
since 12/15/15

Most Recent Stories

More News
Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc.

Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc. Aevi Genomic Medicine (pronounced "AHH-vee") is a name inspired by the Old Norse language...

MDGN : 5.57 (+3.15%)
Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

MDGN : 5.57 (+3.15%)
Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

MDGN : 5.57 (+3.15%)
Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

MDGN : 5.57 (+3.15%)
Medgenics to Present at the Jefferies London Healthcare Conference

PHILADELPHIA, PA--(Marketwired - Nov 9, 2016) -  Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies London Healthcare...

MDGN : 5.57 (+3.15%)
Medgenics Reports Third Quarter 2016 Financial Results

PHILADELPHIA, PA--(Marketwired - Nov 3, 2016) - Medgenics, Inc. (NASDAQ: MDGN)

MDGN : 5.57 (+3.15%)
Medgenics Reports Third Quarter 2016 Financial Results

PHILADELPHIA, PA--(Marketwired - Nov 3, 2016) - Medgenics, Inc. (NASDAQ: MDGN)

MDGN : 5.57 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

Medgenics, Inc. is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company's Biopump Platform Technology uses the patient's own tissue for the treatment of a range of chronic diseases. Its products include EPODURE focused on the treatment of chronic...

See More

Support & Resistance

2nd Resistance Point 5.82
1st Resistance Point 5.69
Last Price 5.57
1st Support Level 5.39
2nd Support Level 5.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.